OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
Jinlin Hou(Southern Medical University), Tarik Asselah(Inserm), Rémi Kazma(Southern Medical University), Maria Teresa Catanese(Rockefeller University), Avinash S. Patil(Southern Medical University), Katerina Glavini(Southern Medical University), Sheng‐Shun Yang(Taichung Veterans General Hospital), Cheng‐Yuan Peng(China Medical University), Man‐Fung Yuen(University of Hong Kong - Shenzhen Hospital), Xieer Liang(Nanfang Hospital), Wenhong Zhang(Fudan University), Cynthia Wat(Roche (United Kingdom)), Edward Gane(University of Auckland), Farouk Chughlay(Southern Medical University), Priyanka Kakrana(Southern Medical University), Cong Cheng(Tianjin University), Yan Huang(Shanghai Pulmonary Hospital), Rui Hua(Jilin University), Ethan Chen(Washington University in St. Louis), Sudip Das(Southern Medical University), Nelson Guerreiro(Southern Medical University), Ruchi Upmanyu(Southern Medical University), Qing Xie(University of Southern California), Hong Tang(Jiangnan University)
Cited by 8
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Clinical Findings in 111 Cases of Influenza A (H7N9) Virus Infection
|New England Journal of Medicine|2013|655